Multinational retrospective study of clinicobiologic features and treatment response in patients with NSCLC harboring a RET fusion

Approximately 1-2% of non-small cell lung cancers (NSCLC) harbor RET fusions. The multinational retrospective RET-MAP study investigated clinicobiologic features and treatment response of patients with any-stage RET+ NSCLC. The study found that patients with RET+ NSCLC had mainly thoracic and bone disease, and low tumor mutational burden and low PD-L1 expression. Treatment with RET-inhibitor significantly improved survival (median: 50.6 months versus 16.3 months with no RET-inhibitor; p<0.0001), while immune checkpoint inhibitors were active in selected patients.